months, there were 13 recurrences in the ATBC− group and 2 in the ATBC+ group. ATBC was associated with a significant survival benefit (99% 40-month disease-free survival for ATBC+ versus 93% for ATBC− cases; P = 0.018). Lack of hormone receptors (HRs) and the presence of lymphovascular invasion (LVI) were significantly associated with a poor prognosis and a greater benefit of ATBC.
Conclusions: ATBC was associated with a significantly reduced risk of recurrence in pT1abN0 HER2+ tumors, and was more beneficial in HR− and/or LVI+ tumors. Key words: HER2 positive, hormone receptors, trastuzumab, T1abN0, vascular emboli introduction Breast tumors overexpressing HER2 (HER2+) account for ∼15% of invasive breast carcinomas [1] . HER2 overexpression is a poor prognostic factor and a positive predictive factor for response to HER2-targeted therapy [1] . Trastuzumab (Herceptin®; Hoffmann-La Roche) is a humanized monoclonal antibody specifically targeting the HER2 protein. Six international, adjuvant, randomized clinical trials published since 2005 have demonstrated significant improvements in disease-free survival (DFS) and overall survival with adjuvant trastuzumab-based chemotherapy (ATBC) in node-positive and/or greater than 1 cm HER2-positive tumors [2] [3] [4] [5] [6] .
Meanwhile, generalized mammographic screening has resulted in the increased detection of smaller breast tumors [7] . Although node-negative tumors ≤1 cm in size ( pT1abN0) have been reported to be associated with an excellent prognosis [8, 9] , prognostic factors for this subset of tumors are similar to those observed for larger tumors [8, [10] [11] [12] . More specifically, many studies have now reported that HER2 overexpression is an independent poor prognosis factor in patients with pT1abN0 breast tumors [11, [13] [14] [15] [16] . However, pT1abN0 HER2+ tumors were excluded from adjuvant trastuzumab trials because of the supposedly favorable prognostic value of small tumor size. Consequently, there are no published data on ATBC efficacy from prospective trials.
Trastuzumab has been available as adjuvant therapy in France since June 2005 thanks to an unrestricted early access program supported by the French National Cancer Institute (INCa). In order to evaluate prescription practices, as well as the potential benefit of ATBC in pT1abN0 HER2+ tumors, the joint UNICANCER/AERIO group launched a retrospective, multicenter study reviewing cases of pT1abN0 HER2+ breast cancers. The study aimed to establish an accurate description of pT1abN0 HER2+ breast cancers and to evaluate the benefit of ATBC in these patients. The interim results of this study, including the first three centers, showed a trend toward a benefit for ATBC on DFS [17] . The study has been extended to eight French cancer centers and updated. This report presents the final results.
patients and methods

study participants
The study was carried out by eight French cancer centers from the UNICANCER group and the French National Association of Residents in Oncology (AERIO, Association d'Enseignement et de Recherche des Internes en Oncologie, www.aerio-oncologie.org). Medical charts were retrospectively reviewed after identification through local databases. Clinical, pathological, and biological data were assessed. Inclusion criteria were invasive carcinoma 2-10 mm in size and prospective determination of HER2 status according to French guidelines from 2001 to 2007 [18, 19] and to ASCO/CAP guidelines from 2007 to 2010 [20] . The eight recruiting centers are reference centers for HER2 status determination in France. Breast pathologists from these centers belong to the French Association for Quality Assurance of Pathology and Cytology (AFAQAP, www.afaqap. com). Their protocols encompass (i) systematic positive/negative controls and (ii) yearly random systematic FISH control of 5% of 3+ HER2 cases. Because HER2 prospective determination did not became routine at the same time in the different centers, first cases were identified between 2001 and 2005 and last cases between 2008 and 2010. Exclusion criteria were neoadjuvant chemotherapy, past medical history of invasive breast carcinoma, and multifocal or multicentric foci.
As endorsed by French guidelines [21] , significant expression of hormone receptors (HRs) was defined as positive estrogen receptor and/or progesterone receptor nuclear immunostaining on ≥10% of invasive cells. Mitotic index (MI) was defined according to the recommendations of Elston and Ellis and was evaluated in 10 high-power fields at ×400 magnification. Elston-Ellis (EE) grade was defined according to international guidelines [22] . Diagnosis of peritumoral lymphovascular invasion (LVI) was based on the examination of hematoxylin-eosin-stained slides. The characteristics of locoregional and systemic treatment were recorded for each patient.
statistical analysis
Statistical analyses were carried out using the R software (http://www.rproject.org/). As most of recurrences occur in HER2+ breast tumors during the first 3 years, results of our study were deemed mature for the final analysis when the median follow-up exceeded 36 months. Because of the differences in follow-up between individuals, events occurring after 60 months of follow-up were censored. In the first analysis, the criteria that triggered the decision to use ATBC were evaluated by multivariate logistic regression analysis with a forward stepwise selection procedure (P-values for entry = 0.10). The benefit of ATBC was evaluated on DFS, defined as the date of diagnosis of primary breast cancer to the date of local, regional, or distal invasive recurrence or death of any cause. Survival distributions were estimated by the Kaplan-Meier method and compared using the logrank test. Differences were considered to be significant if the log-rank Pvalue was <0.05. In order to reduce selection bias, a Cox model was constructed with two factors: ATBC and a propensity score to equate groups [23] based on the criteria identified previously as triggers for the decision to use ATBC. In order to further identify variables associated with DFS, a Cox regression analysis of candidate prognostic factors was carried out using a forward stepwise selection procedure at the P = 0.10 level of significance. In each multivariate analysis, the added value of each variable to the model was determined using a likelihood ratio test. Finally, after the identification of prognostic factors, the consistency of ATBC impact was analyzed in different subgroups, and the interaction between prognostic factors and ATBC was determined. 
criteria for decision to use ATBC
In order to analyze current French prescription practices in pT1abN0 HER2+ tumors, the factors associated with a decision to use ATBC were reviewed by comparing ATBC+ and ATBC− groups. Multivariate analysis with logistic regression showed that the decision to use ATBC was significantly associated with HR− status, high EE grade, tumor size, and patient age ( Table 2 ). The decision to prescribe ATBC outcomes and benefit of ATBC During the median follow-up period of 44 months, there were 16 cases of recurrence and 4 breast cancer-related deaths, corresponding to an overall 40-month DFS of 95.8%. Of the 16 cases of recurrence, 13 were in the ATBC− group, 2 in the ATBC+ group, and 1 in the group given adjuvant chemotherapy alone. In the ATBC− group, 6 out of 13 recurrences were distant metastases (bone, brain, or lung), and Annals of Oncology original article 7 out of 13 were locoregional (with one brain metastasis at second relapse). There were three breast cancer-related deaths. In the ATBC+ group, the two recurrences were locoregional (one with subsequent spread to the liver). The 40-month DFS was 93% for patients who did not receive ATBC versus 99% for ATBC+ patients (log-rank P = 0.018). Kaplan-Meier DFS curves for the ATBC+ and ATBC− groups are shown in Figure 2 . In order to reduce selection bias, a propensity score integrating the four variables involved in the decision to prescribe ATBC (EE grade, HR status, tumor size, and patient age) was calculated for each case. A Cox model was constructed with ATBC and the propensity score. The use of ATBC as an independent good prognostic factor was highly significant in this analysis (P = 0.0006).
factors associated with recurrence
One recurrence out of 19 (5%) occurred in a patient treated with adjuvant chemotherapy without trastuzumab, and no recurrences occurred in the five patients treated with trastuzumab alone. The recurrences in the ATBC− group occurred mostly in HR− patients (8 out of 13 cases). Factors associated with recurrence were explored using a multivariate Cox model (Table 3) . Because of the differences in follow-up between individuals, events occurring after 60 months of follow-up were censored. Only one recurrence occurred after 60 months (in the ATBC− group). In the multivariate Cox model, only three variables were significantly associated with a reduced risk of recurrence: use of ATBC, HR+ status, and absence of LVI.
In an exploratory subgroup analysis, we focused on the two prognostic factors, LVI and HR negative status. Without ATBC, patients with HR− tumors had a 40-month DFS of 84% versus 96% for HR+ cases (log-rank P = 0.0007). ATBC was associated with a significant lower risk of recurrence in HR − cases ( Figure 3A) , with a 40-month DFS of 98% for ATBC+ versus 84% for ATBC− cases (log-rank P = 0.0003). In HR+ cases, the 40-month DFS for ATBC+ cases was 100% versus 96% for ATBC− cases (log-rank P = 0.7). Using a threshold of 1% of stained cells for HR positivity did not alter these results significantly (data not shown).
Without ATBC, patients with LVI+ tumors had a 40-month DFS of 73% versus 96% for LVI− cases (log-rank P = 0.0012). ATBC was associated with a significantly lower risk of recurrence in LVI+ cases ( Figure 3B ) with a 40-month DFS of 100% for ATBC+ cases versus 73% for ATBC− cases (log-rank P = 0.003). In LVI− cases, ATBC was associated with a nonsignificant trend toward a reduced risk of recurrence. In this subset, the 40-month DFS was 99% for ATBC+ cases versus 96% for ATBC− cases (log-rank P = 0.2). It, therefore, seems that HR− and/or LVI+ cases derived a greater benefit from treatment with ATBC. In order to confirm this hypothesis, the patients were divided into two subgroups: (i) LVI+ and/or HR − (n = 140) compared with (ii) all other patients (n = 136). The interaction between ATBC and LVI/HR status was then tested and was found to be at the limit of significance (P = 0.056).
discussion
The incidence of small-sized breast tumors has increased considerably due to their earlier detection by mammographic screening [7] . Indeed, international quality guidelines for breast cancer screening recommend a prevalence objective of at least 20% T1ab in all detected tumors [24] . HER2+ tumors account for 10%-16% of T1abN0 breast tumors [11, 13] . Although the prognostic significance of HER2 overexpression in T1ab tumors is now less debated, the role of ATBC in this subset is still disputed [25, 26] , because no prospective data have been published in T1abN0 HER2+ breast tumors. This report presents the final results from a large, multicenter cohort of pT1abN0 HER2+ patients reporting the use of ATBC.
Four main observations can be made from our analysis. First, pT1abN0 HER2+ tumors were associated with a 40-month DFS rate of 93% in our study like in other reports [11, 13, 14, 16, 27] . Secondly, French clinicians mainly proposed ATBC in patients who presented with additional poor prognostic factors (i.e. HR−, high EE grade, young age, tumor size >5 mm). This has been the case mainly since the implementation of the trastuzumab early-access program by INCa in June 2005. Thirdly, in our experience, ATBC significantly reduced the risk of early relapse in pT1abN0 original article Annals of Oncology HER2+ tumors, with an absolute 6% reduction in recurrence at 40 months (99% versus 93%). Moreover, as shown in Table 2 , the ATBC+ group had a large number of high-risk cases, suggesting that the magnitude of the benefit of ATBC was underestimated. In order to reduce this imbalance, we used a propensity score. The propensity score is a common way to reduce selection bias in retrospective studies [23] . An individual's propensity score is the probability of them being treated conditional to the criteria described previously as triggers for the decision to use ATBC. Cox's multivariate analysis including ATBC and propensity score showed that the use of ATBC was significantly associated (P = 0.0006) with a reduced risk of recurrence. This correction of the nonrandomized nature of our study confirmed the role of ATBC in pT1abN0 HER2+ tumors. The surprisingly high proportion of locoregional recurrences in our series may be interpreted in light of published evidence. Another retrospective, monocenter study of T1abN0 HER2+ patients (n = 99) compared those treated with ATBC with those treated with chemotherapy alone or with no adjuvant medical treatment [28] . The authors observed the same benefit trend as in our study, with a nonsignificant reduction in locoregional, controlateral, and distant invasive recurrence at 36 months with ATBC, and the same group has also shown the potential benefit of trastuzumab in reducing locoregional recurrences [29] . A large British regional study retrospectively reviewed 25 T1abN0 HER2+ cases [30] . Of these cases, seven (28.0%) were treated with ATBC with no relapse (all patients had EE grade 3 cancer, 6 out of 7 were HR−). Of the 18 untreated patients, 2 suffered from recurrence (1 locoregional and 1 metastatic), confirming the benefit trend for ATBC. Furthermore, locoregional occurrences have been evaluated to be as high as 6% in the adjuvant trials. After univariate analysis, four factors were retained for multivariate Cox's analysis. Other variables were non-significant at a threshold of 0.1. 95% CI, 95% confidence interval; NS, P > 0.1 in univariate analysis.
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Our final observation is that HR− and LVI+ seemed to be the most important prognostic factors in our series. Furthermore, the test of interaction showed a trend for a larger benefit of ATBC in HR− and/or LVI+ tumors. Indeed, ATBC was associated with a significant absolute 14% reduction in risk of recurrence in HR− cases and an absolute 27% reduction in LVI+ cases at 40 months. In comparison, ATBC was associated with a non-significant 4% absolute reduction in risk of recurrence at 40 months in HR+ cases and 3% in LVI− cases. The magnitude of the reduction in risk in these latter subsets is smaller and inferior to the generally accepted threshold of a 5% reduction at 5 years to prescribe adjuvant chemotherapy [21] .
Although this is the largest multicenter study of ATBC versus no cytotoxic or anti-HER2 therapy to date, there are several limitations to such retrospective studies. Compared with prospective, randomized, controlled trials (RCTs) of ATBC, the number of patients may seem small; however, the benefit of ATBC on DFS was statistically significant and stable over the follow-up period [17] . Furthermore, HER2+ tumors have a rapid natural evolution. Most recurrences classically occur during the first 2.5 years of follow-up of HER2+ breast tumors [2] [3] [4] [5] [6] . Although our follow-up may seem short (44 months), it exceeds this interval. Another limit is the inability of our study to discriminate between the effects of trastuzumab and chemotherapy. Indeed, adjuvant trastuzumab trials tested the addition of trastuzumab to conventional cytotoxic chemotherapy only. It can then be inferred that trastuzumab exerts its benefit only when combined with conventional chemotherapy. The issue of the benefit of trastuzumab alone in specific subgroups should be addressed by carrying out an RCT, but, to the best of our knowledge, no such study is currently ongoing and would probably had a poor feasibility. Finally, the improved prognosis may not be due to ATBC but to another confounding therapeutic factor such as radiotherapy or surgery. Radiotherapy modalities and the type of surgery were included in the multivariate analysis and were deemed non-significant in this cohort.
Several authors have suggested that ATBC treatment should be discussed for T1bN0 HER2+ tumors [25, 26] and maybe for T1a cases if associated with a high grade [31] . This 6-mm threshold is supported by various European guidelines [32, 33] as well as by the National Comprehensive Cancer Network recommendations (accessed at http://www.nccn.org/ on 15 July 2012). ESMO guidelines are more flexible, allowing ATBC for all T1abN0 HER2+ tumors [34] . In light of the results of the present study, our opinion is that ATBC should be discussed in all pT1abN0 HER2+ cases. Tumor size does not seem to be relevant in this subset. Of course, it is important to assess the risk-benefit ratio for each patient. The incremental gain in survival observed with ATBC in this series cannot be original article Annals of Oncology generalized and possible long-term toxic effects should be taken into consideration in the final decision process [35, 36] . Patients with these tumors should be offered ATBC after giving them a clear explanation about its relative risks and benefits. Evaluation of HR and LVI status may be helpful in selecting patients who would beneficiate more from ATBC. Indeed, in our series, HR− and LVI+ tumors were associated with worse survival and larger absolute benefit of ATBC. The effect of ATBC in T1abN0 HER2+ LVI− HR+ cases in our series was not as clear. The side-effects of chemotherapy and trastuzumab may outweigh the benefit in these cases. Because there are no data on adjuvant trastuzumab alone or with endocrine treatment, we would not recommend relinquishing chemotherapy when adjuvant trastuzumab is considered in T1abN0 HR+ cases. Patients with T1abN0 HER2+ tumors should be included in current adjuvant trials and be given access to HER2-targeted agents.
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